Friday, 16 Feb 2018

You are here

Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis

Arthritis Research and Therapy reports on the epidemiologic association between recurrent anterior uveitis and ankylosing spondylitis (AS) noting that as the number of uveitis episodes increases, so does the incidence of AS.

Uveitis is the most common extra-articular manifestation of AS, occurring in up to 40% of AS patients. As such AS-related anterior uveitis may first present to the ophthalmologist, not by a rheumatologist.  These investigators asked the question - how oftent does recurrent anterior uveitis result in subsequent AS. 

A national cohort of10,483 patients with new-onset uveitis (seen between 2004 -2013) was compared to 52415 matched control subjects (never had uveitis).

After the first uveitis episode, the AS risk was 7 fold higher (incidence rate ratio = 7.4 compared to normal controls).

After the the second uveitis episode, the IRR further increased to 17.71.  High rates of AS were seen in both male and female patients with recurrent uveitis (IRR 284.1 and 268.7 per 100,000 person-years, respectively.

As disease controls, patients with RA or herniatiated vertebral discs did not show a correlation with the occurrence or recurrence of uveitis.

The risk of subsequent AS increased with the number of episodes of anterior uveitis. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioid Use in Ankylosing Spondylitis

A prospective study has shown that ankylosing spondylitis (AS) patients often require narcotic analgesics to manage pain unresponsive to antiinflammatory therapies.

AS patients (n=706) were serially assessed (every 6 months) and outcome measures were collected, including disease activity and functional measures (BASDAI, BASFI), along with radiographic outcomes.  Investigators specifically looked at opioid usage.

Cimzia Limits Xray Progression in Axial Spondyloarthritis

The RAPID-axSpA study of ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients showed that certolizumab pegol (CZP) treatment yielded rapid clinical improvement with limited radiographic progression and MRI inflammation at the sacroiliiac (SI) joint over 4 years.

Apremilast’s Rapid Onset in Psoriatic Arthritis

Monotherapy with apremilast (Otezla) among patients with psoriatic arthritis who were biologic-naive was significantly more effective than placebo as early as week 2 in a phase IIIb study. 

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.